ICON Public Limited Company (ICLR)
| Market Cap | 7.76B -38.2% |
| Revenue (ttm) | 8.10B -2.5% |
| Net Income | 599.48M -19.8% |
| EPS | 7.47 -16.8% |
| Shares Out | 76.36M |
| PE Ratio | 13.67 |
| Forward PE | 8.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,039,317 |
| Open | 102.42 |
| Previous Close | 102.17 |
| Day's Range | 99.37 - 103.12 |
| 52-Week Range | 66.57 - 211.00 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 178.62 (+75.77%) |
| Earnings Date | Apr 30, 2026 |
About ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient... [Read more]
Financial Performance
In 2024, ICLR's revenue was $8.28 billion, an increase of 1.99% compared to the previous year's $8.12 billion. Earnings were $791.47 million, an increase of 29.26%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ICLR stock is "Buy." The 12-month stock price target is $178.62, which is an increase of 75.77% from the latest price.
News
ICON and Advarra Introduce New ‘Research-Ready,' Connected Site Network Model
DUBLIN & COLUMBIA, Md.--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, and Advarra, the market leader in regulatory reviews and a leading provider of connect...
Lowey Dannenberg, P.C. is Investigating ICON PLC (NASDAQ: ICLR) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ICON PLC (“ICON” or the “Company”) (NASDAQ:...
Ademi LLP Investigates Claims of Securities Fraud against ICON plc
MILWAUKEE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities fraud claims against ICON (NASDAQ: ICLR). The investigation results from inaccurate statements ICON may have...
ICLR Investors Have Opportunity to Join ICON Public Limited Company Fraud Investigation with the Schall Law Firm
LOS ANGELES, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ICON Public Limit...
ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement
(NASDAQ: ICLR) NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating ICON plc (NASDAQ: ICLR) following the company's disclosure on February 12, 2026, that an internal accounti...
ICON plc (ICLR) Shares Crater Amid Delayed Financial Report, Investigation Into Revenue Recognition Issues - Hagens Berman
ICLR Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Investors in ICON plc (NASDAQ: ICLR) saw the price of their shares drop about 49% during tra...
ICON plc (ICLR) Shares Crater Amid Delayed Financial Report, Investigation Into Revenue Recognition Issues – Hagens Berman
SAN FRANCISCO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Investors in ICON plc (NASDAQ: ICLR) saw the price of their shares drop about 49% during trading on February 12, 2026, after the company disclosed its ...
Why this drug-research company's stock is having its worst day since 1999
Shares of Icon were plummeting on Thursday toward their worst day in decades, as the announcement of an accounting probe added to all the pressures the contract research organization sector has alread...
ICON PLC (ICLR) Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether ICON Public Limited Company (NASDAQ: ICLR) or its executive officers complied with the federal securities law...
ICLR Down 30%: ICON plc Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
Shares of ICON fell over 30% after the company disclosed that its Audit Committee is conducting an investigation. Investors should contact Block & Leviton.
ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices
DUBLIN--(BUSINESS WIRE)--ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices.
ICON's Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Ca...
ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech tr...
ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites f...
ICON Public Limited Company Transcript: Jefferies London Healthcare Conference 2025
RFP flows and demand are rising, especially in biotech, with large pharma and mid-tier companies increasing activity. Pricing pressure is shifting toward value-based models, and milestone-based contracts now dominate. Margins are under pressure from pass-throughs and lower revenue, but efficiency gains and digital investment are expected to support future growth.
ICON plc to Present at the Jefferies London Healthcare Conference
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the Jefferies London Healthcare Conference.
ICON Public Limited Company Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue and earnings in line with expectations, with strong RFP flow and business awards, but margins pressured by higher pass-through revenue and competitive pricing. Guidance for 2025 was updated, with normalization of cancellations expected in 2026.
ICON Reports Third Quarter 2025 Results
DUBLIN--(BUSINESS WIRE)--ICON Reports Third Quarter 2025 Results.
ICON plc Schedules Third Quarter 2025 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Third Quarter 2025 Earnings Conference Call.
ICON Public Limited Company Transcript: Baird Global Healthcare Conference 2025
A planned CEO transition ensures leadership continuity, with a stable management team and strong customer relationships. Strategic focus remains on expanding in biotech and large pharma, investing in automation, and maintaining high win rates. Financial guidance is unchanged, with optimism for sustained growth and backlog stability.
ICON Announces CEO Transition
DUBLIN--(BUSINESS WIRE)--ICON Announces CEO Transition.
ICON plc to Participate at Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)--ICON plc to Participate at Upcoming Investor Conferences.
ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery
Clinical research organization ICON plc ICLR stock is surging on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2025 sales guidance.
ICON Public Limited Company Earnings Call Transcript: Q2 2025
Q2 2025 delivered sequential revenue and bookings growth, driven by biotech and large pharma partnerships, with strong cost control and operational improvements. Guidance was raised for full-year revenue, but elevated cancellations and a competitive pricing environment persist.
ICON Announces Results of Annual General Meeting
DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.